BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Head and neck liposarcomas: a 32 years experience.

OBJECTIVE: The aim of this review is to study natural history, presentation, treatment and prognosis of head and neck liposarcomas.

Therapeutic modalities included surgery, radiotherapy and chemotherapy.

Histological types of liposarcomas were the following: myxoid (5 cases), well differentiated (4 cases), pleomorphic (4 cases), round cell (1 case) and dedifferentiated (1 case).

After initial treatment, complete remission was achieved in 7 cases (46.7%).

Two of these patients were reoperated and another one received chemotherapy.

In the other 5 cases, the tumor was uncontrollable and no additional treatment has been proposed.

CONCLUSION: The mainstay of treatment of head and neck liposarcomas is surgical excision and the prognosis is largely determined by the histological grade and the clinical stage.

[MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Liposarcoma / pathology. Liposarcoma / therapy

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

(PMID = 19857936.001).

[ISSN] 1879-1476

[Journal-full-title] Auris, nasus, larynx

[ISO-abbreviation] Auris Nasus Larynx

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intradural involvement of multicentric myxoid liposarcoma.

Liposarcomas are malignant tumors of the soft tissue, with myxoid liposarcoma being the second most common subtype, tending to occur in the limbs, particularly in the thighs.

Myxoid liposarcomas have an intermediate prognosis between well-differentiated and pleomorphic tumors.

We present an unusual case of a multicentric myxoid liposarcoma with intradural involvement.

She was histologically diagnosed with small round cell myxoid sarcoma and underwent adjuvant chemotherapy.

However, the patient died of multiple metastases 18 months after the first diagnosis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21082059.001).

[ISSN] 1598-7876

[Journal-full-title] Journal of Korean Neurosurgical Society

[ISO-abbreviation] J Korean Neurosurg Soc

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC2966733

[Keywords] NOTNLM ; Cervical spine / Metastasis / Multicentric / Myxoid liposarcoma / lntradural

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pleomorphic liposarcoma of the uterus: case report and literature review.

A 62-year-old woman with a history of breast carcinoma being treated with tamoxifen presented with a rapidly enlarging pelvic mass.

Microscopic examination revealed a variety of patterns and cell types characteristic of liposarcoma that included myxoid/round cell, storiform/pleomorphic, epithelioid, and spindle cell areas.

The tumor cells were highly pleomorphic with numerous mitotic figures, some of them atypical.

Although a variety of uterine tumors have been associated with tamoxifen treatment, this appears to be the first example of tamoxifen-associated uterine liposarcoma.

[MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Liposarcoma / chemically induced. Liposarcoma / pathology. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / pathology

[MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control

Genetic Alliance. consumer health - Liposarcoma.

MedlinePlus Health Information. consumer health - Uterine Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TAMOXIFEN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 14501826.001).

[ISSN] 0277-1691

[Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

[ISO-abbreviation] Int. J. Gynecol. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen

[Number-of-references] 29

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Radiologically, a tumor in the lower end of the right femur was seen extending into the soft tissue.

The patient received three cycles of neo-adjuvant chemotherapy followed by limb-salvage surgery with provisions for a custom-made prosthesis.

A histopathological study of the excision specimen revealed areas of pleomorphic liposarcoma with numerous osteoblasts associated with areas of osteoid surrounded by neoplastic cells.

The final diagnosis was osteoliposarcoma.

Only 21% tumor necrosis (effects of chemotherapy) was observed.

Presently, 26 months following diagnosis, the patient is fine with no evidence of local recurrence or distant metastasis.

[MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Liposarcoma / diagnosis. Liposarcoma / pathology. Osteosarcoma / diagnosis. Osteosarcoma / pathology

[MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Femur / pathology. Femur / radiography. Humans. Male

MedlinePlus Health Information. consumer health - Bone Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19136790.001).

[ISSN] 0974-5130

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Liposarcoma of the thyroid.

Liposarcoma of the thyroid gland is rare with only 3 cases reported in the English literature.

We present a further two patients whom we have recently treated: a 49 year old lady with a myxoid liposarcoma and a 71 year old man with a pleomorphic liposarcoma.

The former patient died from metastases 10 months after presentation, the latter remains alive but has developed metastatic disease on follow up at 24 months.We recommend the use of high dose radiotherapy following radical surgery as margins of excision are usually narrow in this most difficult region.

The role of chemotherapy is yet to be established.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Radiol. 1998 Oct;71(850):1069-75 [10211068.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]

[Cites] Radiother Oncol. 2001 Aug;60(2):173-80 [11439212.001]

[Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]

[Cites] Sarcoma. 1999;3(3-4):157-65 [18521279.001]

[Cites] Am J Clin Pathol. 1991 May;95(5):675-9 [2024624.001]

[Cites] Tumori. 1986 Oct 31;72(5):499-502 [3798571.001]

[Cites] Cancer. 1984 Mar 15;53(6):1385-92 [6692327.001]

[Cites] Cancer. 1981 May 1;47(9):2269-74 [7226121.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1137-49 [8201375.001]

[Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]

[Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]

[Cites] Am J Surg Pathol. 1997 Feb;21(2):195-200 [9042286.001]

[Cites] Eur J Surg Oncol. 1999 Dec;25(6):606-9 [10556008.001]

(PMID = 18521401.001).

[ISSN] 1357-714X

[Journal-full-title] Sarcoma

[ISO-abbreviation] Sarcoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] Egypt

[Other-IDs] NLM/ PMC2395612

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Liposarcoma of the oral cavity--case reports of the pleomorphic and the dedifferentiated variants and a review of the literature.

Liposarcoma is one of the commonest soft-tissue sarcomas, but very rare in the oral cavity.

We present two cases of liposarcoma of the oral cavity, together with the related clinical, histopathological and immunohistochemical findings: one affecting the cheek of a 62-year-old man and the other the gingival maxillary tuber of a 41-year-old woman.

At histological examination a diagnosis of liposarcoma was made in both cases.

Histological examination and immunohistochemical profiles in the first case were consistent with pleomorphic liposarcoma, whilst that in the second case with dedifferentiated liposarcoma.

Both patients were subjected to surgical treatment with wide surgical margins, without adjuvant radio- or chemotherapy.

We discuss differential diagnosis, examining the histopathological and immunohistochemical features that are potentially useful for distinguishing this tumor from other malignant adipose tissue tumors.

[MeSH-major] Liposarcoma / pathology. Mouth Neoplasms / pathology

Genetic Alliance. consumer health - Liposarcoma.

MedlinePlus Health Information. consumer health - Oral Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17214352.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULT: PGBS occurred in one male and six females with a median age of 70 (range 64-82) years.

Tumors ranged from 1.1 to 4 cm with a median size of 3 cm.

Based on morphological and immunohistochemical features of the PGBS, there were three myxofibrosarcomas (malignant fibrous histiocytoma, MFH, storiform pleomorphic), one leiomyosarcoma (LMS), one angiosarcoma (AS), and two liposarcomas (LS).

All patients received cholecystectomy and three received adjuvant chemotherapy.

Follow-up revealed that six patients died of the disease 6 weeks to 2 years after diagnosis and one died of unrelated causes.

A variety of sarcoma types are found with MFH being the predominant variant.

MedlinePlus Health Information. consumer health - Gallbladder Cancer.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]

[Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):91-102 [7123848.001]

[Cites] Acta Chir Belg. 2004 Feb;104(1):107-9 [15053476.001]

[Cites] Histopathology. 1994 Mar;24(3):269-71 [7726886.001]

[Cites] Am J Gastroenterol. 1986 Mar;81(3):202-4 [3513545.001]

[Cites] Gut. 1994 Jun;35(6):854-6 [8020820.001]

[Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]

[Cites] Rev Invest Clin. 1989 Apr-Jun;41(2):159-64 [2781178.001]

[Cites] Am Surg. 2001 Jul;67(7):714-7 [11450796.001]

[Cites] Am J Surg Pathol. 2000 Oct;24(10):1420-3 [11023105.001]

[Cites] Acta Oncol. 1998;37(2):212-4 [9636020.001]

[Cites] Cancer. 1982 Feb 15;49(4):812-8 [7055789.001]

[Cites] Arch Pathol Lab Med. 2002 Apr;126(4):481-3 [11900579.001]

[Cites] Virchows Arch A Pathol Anat Histol. 1982;396(2):225-30 [6289513.001]

[Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]

[Cites] Indian J Pathol Microbiol. 1993 Jan;36(1):78-80 [8354563.001]

[Cites] Am J Surg Pathol. 1984 May;8(5):323-33 [6731662.001]

[Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]

[Cites] Histopathology. 1987 Feb;11(2):209-14 [2437004.001]

[Cites] Cancer. 1980 Mar 1;45(5):919-27 [7260842.001]

[Cites] Hum Pathol. 1993 Dec;24(12):1298-305 [8276377.001]

[Cites] J Gastrointest Surg. 2008 Mar;12(3):609-11 [17768664.001]

[Cites] Ann Diagn Pathol. 1999 Apr;3(2):75-80 [10196386.001]

[Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]

[Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]

[Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]

[Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]

[Cites] Arch Pathol Lab Med. 1995 Dec;119(12):1173-6 [7503670.001]

[Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):822-5 [15985238.001]

[Cites] Surg Today. 2002;32(1):81-5 [11871825.001]

[Cites] Am J Surg Pathol. 2007 Oct;31(10):1598-604 [17895763.001]

[Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]

[Cites] Mil Med. 1992 Oct;157(10):559-61 [1454184.001]

(PMID = 18618258.001).

[ISSN] 1573-2568

[Journal-full-title] Digestive diseases and sciences

[ISO-abbreviation] Dig. Dis. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A rare primary tumor of the mediastinum: pleomorphic liposarcoma].

[Transliterated title] Une tumeur primitive rare du médiastin: le liposarcome pléomorphe.

Liposarcoma of the mediastinum is a rare tumor with various histologic features.

We report a case of mediatinal pleomorphic liposarcoma in a 37-year-old man who complained of chest pain.

Computed tomography showed an anterior expansive process within the mediastinum.

Histological diagnosis was established by a trans-thoracic computed tomography guided core-needle biopsy.

Despite a first cure of chemotherapy with gemcitabin/cisplatin, disease progression led to death 3 months after diagnosis.

Mediastinal pleomorphic liposarcoma is an exceptional invading tumor affecting the middle-aged adult.

Surgery is the best treatment when possible.

The role of radiotherapy and chemotherapy are discussed.

[MeSH-major] Liposarcoma / pathology. Mediastinal Neoplasms / pathology

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chest Pain / etiology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fatal Outcome. Humans. Male

Genetic Alliance. consumer health - Liposarcoma.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18166943.001).

[ISSN] 0761-8417

[Journal-full-title] Revue de pneumologie clinique

[ISO-abbreviation] Rev Pneumol Clin

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] France

[Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Liposarcoma histologic subtypes: four cases reports].

[Transliterated title] Subtipos histológicos de liposarcoma: presentación de cuatro casos.

The liposarcoma is a malignant tumor of mesodermic origin derived of the adipose tissue.

Liposarcoma s types, according to his histological diagnosis, are: mixoide, pleomorphic, well differentiated and dedifferentiated.

His treatment is the radical surgery, it is possible, together with radiation therapy and/or chemotherapy.

Four patients diagnosed of liposarcoma are shown up, a case of liposarcoma well differentiated, another case of liposarcoma pleomorphic and two cases about liposarcoma mixoide; with the characteristic that one of these two cases presented a local recidivation with a dediferenciation of itself.

[MeSH-major] Abdominal Neoplasms / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology

[MeSH-minor] Abdomen / pathology. Aged. Diagnosis, Differential. Female. Humans. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / pathology. Liposarcoma, Myxoid / radiography. Liposarcoma, Myxoid / surgery. Male. Middle Aged. Prognosis. Radiography, Abdominal. Retroperitoneal Space / pathology. Tomography, X-Ray Computed. Treatment Outcome

Genetic Alliance. consumer health - Liposarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17867902.001).

[ISSN] 0212-7199

[Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)

[ISO-abbreviation] An Med Interna

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pleomorphic liposarcoma.

Pleomorphic liposarcoma (PLS) is defined as a high-grade pleomorphic sarcoma containing multivacuolated lipoblasts.

Older age, female sex, epithelioid phenotype, and radiotherapy or chemotherapy administration were not significantly associated with an adverse outcome.

[MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology

Genetic Alliance. consumer health - Liposarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 11757868.001).

[ISSN] 0740-2570

[Journal-full-title] Seminars in diagnostic pathology

[ISO-abbreviation] Semin Diagn Pathol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 78

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fulminant course of metastatic liposarcoma after delivery--case report.

Abdominal liposarcoma is a rare tumor of uncertain prognosis.

Only a few cases of liposarcoma complicating pregnancy have been documented.

We report a case of a patient who was diagnosed with metastatic abdominal liposarcoma during the third trimester of the pregnancy.

After induced vaginal delivery, palliative surgery was performed and one cycle of systemic combination chemotherapy was administered.

Despite the multimodality treatment the patient died of progressive disease within one month after diagnosis.

Autopsy revealed high-grade pleomorphic liposarcoma arising from the retroperitoneum with liver and lung metastases.

[MeSH-major] Liposarcoma / diagnosis. Liposarcoma / secondary. Pregnancy Complications, Neoplastic / diagnosis. Retroperitoneal Neoplasms / diagnosis

Genetic Alliance. consumer health - Liposarcoma.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17375713.001).

[ISSN] 0392-2936

[Journal-full-title] European journal of gynaecological oncology

[ISO-abbreviation] Eur. J. Gynaecol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A case of pleomorphic liposarcoma involving a parahypopharyngeal site].

[Transliterated title] Su un caso di liposarcoma pleomorfo a sede paraipofaringea.

Soft tissue sarcomas are uncommon, accounting for fewer than 1% of malignant neoplasms of the head and neck.

The most frequent histotype is malignant fibrohistiocytoma (29%), while the least common is liposarcoma (1%).

We report the case of a 20-year-old man with a malignant hypopharyngeal pleomorphic liposarcoma, successfully treated with surgery and adjuvant radio- and chemotherapy.

[MeSH-major] Hypopharyngeal Neoplasms / therapy. Liposarcoma / therapy

[MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

Genetic Alliance. consumer health - Liposarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12872584.001).

[ISSN] 0009-4773

[Journal-full-title] Chirurgia italiana

[ISO-abbreviation] Chir Ital

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy].

We report a case of postoperative recurrence of liposarcoma of the mesenterium successfully treated by chemotherapy using ifosfamide (IFM) and cisplatin (CDDP).

A 58-year-old man presented with a strange feeling in the lower abdomen.

Enhanced computed tomography showed enhanced non-epithelial tumor in the pelvic space.

The tumor moved on palpation, so we diagnosed liposarcoma from the mesenterium, and resected the tumor on 22 August, 2002.

The pleomorphic liposarcoma was 11 x 14 x 7 cm, growing from the mesenterium of the sigmoid colon, and weighed 640 g.

We started chemotherapy 3 days later using 3.0 g/body IFM from 1 October 2003, together with 1,800 mg/body mesna for prevention of hemorrhage cystitis.

We continued chemotherapy using 3.0 g/body/day IFM together with 1, 800 mg/body/day mesna on an outpatient basis, upon his weekly visit to the hospital.

Patient remission was shown by abdominal enhanced computed tomography on 10 December.

Some grade 2 alopecia and grade 2 leukopenia occurred, so we changed to chemotherapy once every two weeks.

The response appeared to be complete on computed tomography in August 2004, and we have been continuing the same chemotherapy without recurrence.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Mesentery. Neoplasm Recurrence, Local / drug therapy. Peritoneal Neoplasms / drug therapy

[MeSH-minor] Cisplatin / administration & dosage. Colon, Sigmoid. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Postoperative Period. Remission Induction. Reoperation

Genetic Alliance. consumer health - Liposarcoma.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. IFOSFAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16685172.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas of elderly patients and has a predilection for the limbs.

Fifteen patients presented with a mass, and in 2 of these there was also pain.

In 10 cases, the tumor was located in subcutaneous tissue and in 6 cases it was subfascial.

Twelve patients were treated by surgery followed by chemotherapy and/or radiation (8 cases).

One patient received chemotherapy after an incisional biopsy and 1 patient was treated by surgery alone.

Ten patients (71.4%) developed local recurrences.

Seven patients (50%) developed metastases to lungs or retroperitoneum.

Differential diagnosis included carcinoma, melanoma, myoepithelial carcinoma, pleomorphic liposarcoma, and pleomorphic rhabdomyosarcoma.

[MeSH-major] Epithelioid Cells / pathology. Fibrosarcoma / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Extremities. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Liposarcoma / diagnosis. Male. Melanoma / diagnosis. Middle Aged. Myoepithelioma / diagnosis. Rhabdomyosarcoma / diagnosis

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17197925.001).

[ISSN] 0147-5185

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Retroperitoneal pleomorphic liposarcoma. A case of survival after ten years].

[Transliterated title] Liposarcoma pleomorfo retroperitoneale. Dieci anni di sopravvivenza.

Sarcomas are malignant neoplasms which can involve both soft tissues and/or bones.

The soft tissues sarcomas are very rare, representing about 1% of all malignant tumors.

Currently, surgery is the only curative therapy for soft tissues sarcomas in adult patients, with the exclusion of retroperitoneal sarcomas, which have have poor prognosis, due to look of surgical radicality and low radiotherapy and chemotherapy responsiveness.

In fact, chemotherapy by conventional regimens, as adriamicine plus ifosfamide or CYVADIC, allows not more than 25% of partial responses, with a median survival of 12 months.

[MeSH-major] Liposarcoma / therapy. Retroperitoneal Neoplasms / therapy

[MeSH-minor] Aged. Humans. Male. Survivors. Time Factors

Genetic Alliance. consumer health - Liposarcoma.

Genetic Alliance. consumer health - Retroperitoneal liposarcoma.

Genetic Alliance. consumer health - TEN.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15032338.001).

[ISSN] 0034-1193

[Journal-full-title] Recenti progressi in medicina

[ISO-abbreviation] Recenti Prog Med

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.

Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care.

Usually large at presentation they present particular challenges for both local treatment and systemic control.

The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma).

Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease.

Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.

[MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy

[MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Combined Modality Therapy. Drug Delivery Systems. Humans. Palliative Care / methods. Radiotherapy, Adjuvant / methods

Genetic Alliance. consumer health - Soft tissue sarcoma.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19671034.001).

[ISSN] 1744-8328

[Journal-full-title] Expert review of anticancer therapy

[ISO-abbreviation] Expert Rev Anticancer Ther

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 93

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differential sensitivity of liposarcoma subtypes to chemotherapy.

Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic.

However, the response of these subgroups to chemotherapy is not well documented.

In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital.

Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified.

The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated.

A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28-69) and 11% (95%CI; 2-29), P = 0.005.

Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28-69) and 18% (95%CI; 8-31).

This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours.

[MeSH-major] Antineoplastic Agents / therapeutic use. Liposarcoma, Myxoid / drug therapy

[MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Liposarcoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16289617.001).

[ISSN] 0959-8049

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.

The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.

For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made via the rapid development and approval of the targeted therapy imatinib.

Small round cell tumours (SRCTs), such as Ewing's sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease.

Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy.

In relapsed 'adult type' soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile.

It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited.

Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.

[MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology

[MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Humans

Genetic Alliance. consumer health - Soft tissue sarcoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anticancer Drugs. 2002 May;13 Suppl 1:S7-9 [12173492.001]

[Cites] J Clin Oncol. 2002 Mar 1;20(5):1329-34 [11870176.001]

[Cites] Cancer Treat Rep. 1976 Feb;60(2):199-203 [769974.001]

[Cites] Ann N Y Acad Sci. 1996 Dec 13;803:224-30 [8993516.001]

[Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]

[Cites] Am J Clin Oncol. 2002 Dec;25(6):561-4 [12477998.001]

[Cites] Gynecol Oncol. 2003 Apr;89(1):48-51 [12694653.001]

[Cites] J Clin Oncol. 1996 Dec;14(12):3062-73 [8955651.001]

[Cites] Eur J Cancer. 2003 Jun;39(9):1318-29 [12763223.001]

[Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]

[Cites] Cancer. 2003 Jun 1;97(11):2848-52 [12767099.001]

[Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]

[Cites] Cancer Res. 2001 Mar 15;61(6):2579-82 [11289134.001]

[Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]

[Cites] Invest New Drugs. 2002 Feb;20(1):129-32 [12003189.001]

[Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]

[Cites] Expert Opin Investig Drugs. 2000 Jul;9(7):1545-51 [11060759.001]

[Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]

[Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]

[Cites] Cancer Chemother Pharmacol. 1991;27(5):342-6 [1998993.001]

[Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1899-901 [12820475.001]

[Cites] Cancer Chemother Pharmacol. 1995;36(3):263-5 [7781149.001]

[Cites] Eur J Cancer. 1999 Mar;35(3):410-2 [10448291.001]

[Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]

[Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]

[Cites] Cancer. 2003 Apr 15;97(8):1969-73 [12673725.001]

[Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]

[Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]

[Cites] Anticancer Drugs. 1999 Jun;10(5):453-6 [10477164.001]

[Cites] Br J Cancer. 2003 Oct 20;89(8):1409-12 [14562008.001]

[Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]

[Cites] Ann Oncol. 1995 Oct;6(8):847-9 [8589028.001]

[Cites] Clin Ter. 1999 Jan-Feb;150(1):17-20 [10367540.001]

[Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]

[Cites] J Clin Oncol. 2001 Jun 1;19(11):2937-47 [11387367.001]

[Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]

[Cites] Ann Oncol. 2004 Apr;15(4):671-9 [15033678.001]

[Cites] Cancer. 1995 Dec 1;76(11):2248-52 [8635028.001]

[Cites] Cancer Res. 1991 Dec 15;51(24):6636-42 [1742737.001]

[Cites] Anticancer Drugs. 1999 Nov;10(10):873-7 [10630354.001]

[Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]

[Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]

[Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]

[Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]

[Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]

[Cites] Cancer. 2003 Dec 15;98 (12 ):2693-9 [14669291.001]

[Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]

[Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]

[Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]

[Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]

[Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S174-9 [8453693.001]

[Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]

[Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]

[Cites] J Med Chem. 1984 Feb;27(2):196-201 [6694168.001]

[Cites] J Med Chem. 1986 Aug;29(8):1553-5 [3735324.001]

[Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]

[Cites] Cancer. 1997 Oct 1;80(7):1221-7 [9317171.001]

[Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]

[Cites] Eur J Cancer. 1998 Feb;34(3):422-3 [9640234.001]

[Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]

[Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]

(PMID = 15631540.001).

[ISSN] 0012-6667

[Journal-full-title] Drugs

[ISO-abbreviation] Drugs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] New Zealand

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 72

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnosis and management of lipomatous tumors.

Lipomatous tumors range from benign lipomas to high-grade liposarcomas.

Liposarcomas are classified into five histologic subtypes: well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic, which differ in outcomes and patterns of recurrence.

Surgical resection is the mainstay of curative treatment; however, large, high grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation.

Prospective randomized clinical trials will continue to improve our care of patients with liposarcoma.

[MeSH-major] Liposarcoma / diagnosis. Liposarcoma / therapy

[MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Lipoma / diagnosis. Lipoma / pathology. Lipoma / therapy. Prognosis

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18286473.001).

[ISSN] 0022-4790

[Journal-full-title] Journal of surgical oncology

[ISO-abbreviation] J Surg Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 84

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog.

We report a liposarcoma at the mesojejunoileum that was widely excised, and then the intrahepatic metastatic liposarcoma was found.

The dog was treated by two single-agent chemotherapy separately.

Final diagnosis of a pleomorphic liposarcoma was made by the routine histology and further identified by Oil Red O stain.

The two single-agent chemotherapy including doxorubicin followed by capecitabine, however, failed to cause remission of the intrahepatic metastatic lesions.

The patient died 22 months after operation and the cause of death was supposed to be metastatic liposarcoma.

MedlinePlus Health Information. consumer health - Intestinal Cancer.

MedlinePlus Health Information. consumer health - Liver Cancer.

Hazardous Substances Data Bank. CAPECITABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18628610.001).

[ISSN] 0916-7250

[Journal-full-title] The Journal of veterinary medical science

[ISO-abbreviation] J. Vet. Med. Sci.

[Language] ENG

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].

In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.

As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.

However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.

Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.

On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.

Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.

Among them, the key drugs are adriamycin and ifosfamide.

For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.

Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.

Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.

[MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology

[MeSH-minor] Combined Modality Therapy. Humans

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19223736.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents